Calidi Biotherapeutics, Inc. (CLDI) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: August 22, 2025
Calidi Biotherapeutics, Inc. (CLDI) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
Calidi Biotherapeutics, Inc. (Stock Symbol: CLDI)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Market Capitalization: $6 million - Classified as a
small-cap investment offering high growth potential.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Calidi Biotherapeutics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
Calidi Biotherapeutics, Inc. strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
Calidi Biotherapeutics, Inc. Stock Price Chart and Technical Analysis
Loading chart data...
Loading Calidi Biotherapeutics, Inc. interactive price chart and technical analysis...
Deep dive into Calidi Biotherapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if Calidi Biotherapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For Calidi Biotherapeutics, Inc.: With a P/E ratio of -0.92, the market sees the stock as potentially undervalued.
P/E Ratio-0.92x
P/B Ratio3.34x
Market Cap$6M
EPS$-5.14
Book Value/Share$0.52
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently Calidi Biotherapeutics, Inc. converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For Calidi Biotherapeutics, Inc.:
Understanding Financial Health Metrics
What these metrics mean: These ratios assess Calidi Biotherapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For Calidi Biotherapeutics, Inc.:
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal Calidi Biotherapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For Calidi Biotherapeutics, Inc.:
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively Calidi Biotherapeutics, Inc. uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For Calidi Biotherapeutics, Inc.:
Understanding Financial Statement Data
What these metrics mean: Key figures from Calidi Biotherapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For Calidi Biotherapeutics, Inc.:
Income Statement ($ Millions)
Net Income$12M
R&D Expense$10M
Balance Sheet Highlights ($ Millions)
Dividend & Shareholder Information
Shares Outstanding3M
Growth Metrics (YoY)
EPS Growth-125.8%
Calidi Biotherapeutics, Inc. (CLDI) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Calidi Biotherapeutics, Inc. stock analysis.
Loading fundamental data...
Loading Calidi Biotherapeutics, Inc. comprehensive fundamental analysis and insider trading data...
Latest Calidi Biotherapeutics, Inc. Stock News & Market Analysis
Breaking news, analyst reports, and market updates affecting Calidi Biotherapeutics, Inc. (CLDI) stock price and investment outlook.
Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) ('Calidi” or the 'Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver ...
Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver ...
An announcement from Calidi Biotherapeutics ( (CLDI) ) is now available. On August 20, 2025, Calidi Biotherapeutics announced an underwritten public offering, raising approximately $6.9 million ...
Calidi Biotherapeutics Inc. is taking a bold approach to this challenge with a next-generation platform designed to deliver genetic medicines directly to both primary and metastatic tumors.
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted ...
LA JOLLA, Calif.--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering the development of stem cell-based delivery of oncolytic viruses, has been ...
Calidi Biotherapeutics Inc. is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease.
Calidi Biotherapeutics Inc. is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease.
Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the pricing of its" reasonable best efforts" public ...
Calidi Biotherapeutics Inc. is taking a bold approach to this challenge with a next-generation platform designed to deliver genetic medicines directly to both primary and metastatic tumors.
Calidi Biotherapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of Calidi Biotherapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
Frequently Asked Questions - Calidi Biotherapeutics, Inc. Stock Forecast
How accurate are Calidi Biotherapeutics, Inc. stock predictions?
Our AI model demonstrates 37% historical accuracy for CLDI predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence Calidi Biotherapeutics, Inc. stock price forecasts?
Is Calidi Biotherapeutics, Inc. a good investment in 2025?
Based on our AI analysis, Calidi Biotherapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are Calidi Biotherapeutics, Inc. forecasts updated?
Calidi Biotherapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced Calidi Biotherapeutics, Inc. Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Calidi Biotherapeutics, Inc. stock.
